# Health Check: BlinkLab shares surge on breakthrough ADHD detection results > Source: > Published: 2026-08-05 02:07:53+00:00 # Health Check: BlinkLab shares surge on breakthrough ADHD detection results **Following positive European trial results, BlinkLab is taking its ADHD program a step further****Adalta reports “highly encouraging” mesothelioma study results****Neuren sales partner ups Daybue sales guidance after record quarter** ** ** [ BlinkLab (ASX:BB1)](https://stockhead.com.au/company/blinklab-bb1/) will pursue US approval of its algo-based attention deficit hyperactivity disorder (ADHD) diagnosis tool, having posted positive results from a European study. Covering children aged six to 17, the study achieved sensitivity of 82% and specificity of 83%. Sensitivity is the ability to detect a condition while specific is the ability to rule one out. “The study cohort represents one of the largest case-control datasets reported for ADHD assessment tools,” the company said. “The findings support development of BlinkLab Dx2, the company’s novel AI model designed to detect ADHD in addition to autism using smartphone tracking of digital neurobehavioural biomarkers.” BlinkLab will now prepare for a US study – a similar path the company took with its autism tool, unsurprisingly dubbed BlinkLab Dx1. The company undertook the European study in collaboration with Mental Care Group (MCG), at no cost to BlinkLab. The trial collected neurometric data from children recruited across multiple MCG centres in the Netherlands. These were supplemented by neurotypical candidates from the community (the control group). Participants completed brief smartphone-based assessments. These aimed to collect digital neurobehavioural biomarkers, including “subtle and involuntary” behaviours such as blinking or facial reflexes. The study enrolled 375 kids, but this number reduced to 208 after it excluded subjects on medication or with other neurodevelopmental conditions. Of the 208 children analysed, 117 (56%) had a confirmed ADHD clinical diagnosis, while 91 (44%) had not. The algo then identified the positive ADHD diagnosis in 82% of cases and cleared the comparison group 83% of the time. “ADHD is a significant unmet medical need and – in our view – a substantially larger addressable market than paediatric autism,” BlinkLab CEO Dr Henk-Jan Boele said. The company notes that no blood test or brain scan currently exists for ADHD. Diagnosis depends on clinical judgements – and even two experienced clinicians can disagree. “The results provide the first evidence that digital neurobehavioural biomarkers can detect differences associated with ADHD,” BlinkLab said. In the blink of an eye, BlinkLab shares advanced as much as 15%. The stock has gained 70% over the last 12 months. **AdAlta’s ‘significant durability’ trial milestone** [ AdAlta (ASX:1AD)](https://stockhead.com.au/company/adalta-1ad/) reports the first patient to achieve a complete response in its advanced mesothelioma trial has passed the two-year mark without any cancer recurrence. A complete response is when a tumour completely disappears and is akin to a cure. Another complete responder has passed the one-year survival milestone. AdAlta is trialling its acquired Car-T therapy, called EW-001 (previously BZDS-1901). The program is under the auspices of the company’s subsidiary, AdCella, which seeks to source promising Asian therapies and commercialise them. Indeed, Shanghai Cell Therapy Group is carrying out the study, in China. Overall, the study enrolled 14 patients. The two complete responders were among 10 patients treated at higher doses. “Complete tumour clearance is almost never seen in patients with advanced mesothelioma,” AdAlta CEO Tim Oldham said. “To have achieved it in … 20% of patience is highly encouraging.” AdAlta will “continue to follow all patients in the study and report additional survival and response data as they emerge”. Meanwhile the company is preparing to meet the US Food and Drug Administration (FDA), in view of obtaining Investigational New Drug status. Mesothelioma is a rare but rapidly fatal cancer of the membranes surrounding the lungs, heart and gastrointestinal organs. It is usually associated with asbestos exposure. “Patients are typically treated initially with chemotherapy or immunotherapy,” the company said. “Once the disease has returned or progressed following these treatments, therapeutic options are limited and clinical outcomes are generally poor”. AdAlta shares climbed as much as 14% this morning. **Amplia’s lung cancer collab wins praise** Broker Bell Potter sees considerable upside for cancer drug developer [ Amplia (ASX:ATX)](https://stockhead.com.au/company/amplia-atx/) after yesterday’s announcement of non-small cell lung cancer (NSCLC) clinical collab with Big Pharma Eli Lilly. Amplia hitherto had posted outstanding complete response results with its pancreatic cancer program. Along with ovarian cancer, NSCLC is another potential use for Amplia’s focal kinase inhibitor, narmafotinib (AMP-945). The proposed phase Ib/IIb trial combines narmafotinib with Lilly’s Kras inhibitor, olomorasib. Amplia funds the trial, while Lilly provides its drugs and clinical expertise. Bell Potter opines the tie-up confers “considerable credibility and validation for narmafotinib”, given Lilly would have undergone considerable due diligence. It notes Lilly is “flush with cash” after divesting GLP-1 assets. The drug combo targets 13% of cancers displaying the relevant G12C mutation, whereas only 1-2% of pancreatic cancers do so. Bell Potter ascribes a speculative buy call and a 42 cents per share valuation, implying 230% of upside. **Neuren’s partner ups Daybue sales guidance** [ Neuren Pharmaceuticals’ (ASX:NEU)](https://stockhead.com.au/company/neuren-pharmaceuticals-neu/) global commercial partner Acadia Pharmaceuticals has boosted full-year sales guidance after a record June quarter for the Rett syndrome drug Daybue (trofinetide). June (second) quarter net sales came in at US$125m, 30% higher year on year and 24% better than the March quarter. Sales growth was “almost entirely” volume driven, which implies that Acadia couldn’t – or didn’t – raise prices. Neuren calls out the performance of the more convenient dosing powder formula, Daybue Stix. For Neuren, this revenue translated to royalty income of US$12.9m, up 34% year on year. Acadia upped calendar 2026 net sales guidance to US$480-510m, from US$460-490m previously. This implies full-year royalty income for Neuren of US$53-56m (previously US$50-54m). Acadia also reaffirmed targeted Daybue net sales of US$700m for the 2027-28 year. Currently Acadia sells Daybue mainly in the US. But Neuren/Acadia plan to launch Daybue in Germany by the end of the year, pending European Commission approval. The parties also are carrying out a Japanese trial, in view of a regulatory submission there next year. Off its own bat, Neuren is conducting a phase III trial for Phelan-McDermid syndrome, dubbed Koala. **Memphasys in Pole position for baby bounce** Poland’s birth rate reportedly is less than that of even reproductive-shy Japan, but sperm sorter-outer [ Memphasys (ASX:MEM)](https://stockhead.com.au/company/memphasys-mem/) has come to the rescue. The company has signed an exclusive commercialisation deal with Polish diagnostics distributor TK Biotech, to sell its Felix device in the country. Felix separates good sperm from dud ones, for IVF purposes. The deal involves TK Biotech purchasing a minimum of $350,000 of product over two years. This tie-up marks Memphasys’ third European deal, since winning CE Mark clearance for Felix last December. The company has similar compacts in the UK and Italy. With Poland’s birthrate well beyond the population’s replacement rate, Warsaw introduced a publicly-funded IVF program in 2024. ## Related Topics ### UNLOCK INSIGHTS Discover the untold stories of emerging ASX stocks. Daily news and expert analysis, it's free to subscribe. By proceeding, you confirm you understand that we handle personal information in accordance with our [Privacy Policy](https://stockhead.com.au/privacy-policy/).